Metastatic renal cell cancer

Cancer Imaging

Volumn 13, Issue 3, 2013, Pages 374-380

  Rasmussen, Finn ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

MRCC; Renal cell carcinoma; Targeted therapy

Indexed keywords

ACETIC ACID C 11; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; SUNITINIB;

ANGIOGENESIS; APPARENT DIFFUSION COEFFICIENT; CANCER PROGNOSIS; CAPILLARY DENSITY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG CHOICE; DRUG MONITORING; DRUG TARGETING; DYNAMIC CONTRAST ENHANCED ULTRASONOGRAPHY; ECHOGRAPHY; EMISSION TOMOGRAPHY; FOLLOW UP; HUMAN; ISOTOPE LABELING; KIDNEY CANCER; KIDNEY METASTASIS; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME; VASCULARIZATION;

CARCINOMA, RENAL CELL; CONTRAST MEDIA; HUMANS; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84885625180     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2013.9035     Document Type: Conference Paper

References (34)

1. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58: 398-406
2. Martel CL, Lara PN. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol 2003; 45: 177-190 (Pubitemid 36221342)
3. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119-1132
4. Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA 1999; 28: 1628-1631 (Pubitemid 29211773)
5. Diederich S. Imaging beyond RECIST: CT and MRI in molecular therapies. Cancer Imaging 2012; 12: 347-350
6. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124 (Pubitemid 46089672)
8. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010; 102: 803-809
9. Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 2010; 21: 936-941
10. Krajewski KM, Guo M, Van den Abbeele AD, et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factortargeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011; 59: 856-862
11. Wang JH, Min PQ, Wang PJ, et al. Dynamic CT evaluation of tumor vascularity in renal cell carcinoma. Am J Roentgenol 2006; 186: 1423-1430
12. Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 2000; 7: 840-850
13. Baccala A, Jr. Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007; 14: 1095-1097 (Pubitemid 350151265)
14. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumour treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759 (Pubitemid 46797957)
15. Hittinger M, Staehler M, Schramm N, et al. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. Urol Oncol 2012; 30: 695-703
16. Nathan PD, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010; 9: 15-19
17. Han KS, Jung DC, Choi HJ, et al. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer 2010; 116: 2332-2342
18. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrastenhanced CT. AJR Am J Roentgenol 2010; 194: 157-165
19. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010; 194: 1470-1478 doi:10.2214/AJR.09.3456. PubMed PMID: 20489085.
20. Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, Miles KA. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 2011; 261: 165-171
21. Reiner CS, Roessle M, Thiesler T, et al. Computed tomography perfusion imaging of renal cell carcinoma: systematic comparison with histopathological angiogenic and prognostic markers. Invest Radiol 2013; 48: 183-191
22. Chen Y, Zhang J, Dai J, Feng X, Lu H, Zhou C. Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging 2010; 35: 622-628
23. Fournier LS, Oudard S, Thiam R, et al. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010; 256: 511-518
24. Ng CS, Wang X, Faria SC, Lin E, Charnsangavej C, Tannir NM. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol 2010; 194: 166-171
25. Miles KA, Lee TY, Goh V, et al. Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol 2012; 22: 1430-1441
26. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCEMRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008; 7: 496-501 (Pubitemid 351847022)
27. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008; 26: 4572-4578
28. Taouli B, Thakur RK, Mannelli L, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 2009; 251: 398-407
29. Desar IM, ter Voert EG, Hambrock T, et al. Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging 2012; 11: 259-265
30. Lassau N, Koscielny S, Albiges L, et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010; 16: 1216-1225
31. Aide N, Cappele O, Bottet P, et al. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003; 30: 1236-1245 (Pubitemid 37205377)
32. Majhail NS, Urbain JL, Albani JM, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003; 21: 3995-4000 (Pubitemid 46606214)
33. Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 2011339-343
34. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007; 8: 304-310 (Pubitemid 46464522)